An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice

References

• Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Locher CP, Paidhungat M, Richards MJ, Lind CM, Bakken R, Parker MD, Whalen RG, Schmaljohn CS. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine 2009; 27:4152-60; PMID:19406186; https://doi.org/10.1016/j.vaccine.2009.04.049
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine 2010; 28:7345-50; PMID:20851089; https://doi.org/10.1016/j.vaccine.2010.09.005
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol 2011; 18:707-16; PMID:21450977; https://doi.org/10.1128/CVI.00030-11
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246:134-44; PMID:9657001; https://doi.org/10.1006/viro.1998.9176
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Hum Vaccin Immunother 2012; 8:1703-6; PMID:22922764; https://doi.org/10.4161/hv.21873
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, et al. Codon-Optimized Filovirus DNA Vaccines Delivered by Intramuscular Electroporation Protect Cynomolgus Macaques from Lethal Ebola and Marburg Virus Challenges. Hum Vaccines Immunotherapeutics 2015; 11:1991-2004, in press; https://doi.org/10.1080/21645515.2015.1039757
   PubMed Web of Science ®Google Scholar
• Hart MK, Pratt W, Panelo F, Tammariello R, Dertzbaugh M. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine 1997; 15:363-9; PMID:9141206; https://doi.org/10.1016/S0264-410X(96)00204-6
   PubMed Web of Science ®Google Scholar
• Phillpotts RJ, Jones LD, Howard SC. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 2002; 20:1497-504; PMID:11858855; https://doi.org/10.1016/S0264-410X(01)00505-9
   PubMed Web of Science ®Google Scholar
• Phillpotts RJ, O'Brien L, Appleton RE, Carr S, Bennett A. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 2005; 23:1615-23; PMID:15694514; https://doi.org/10.1016/j.vaccine.2004.06.056
   PubMed Web of Science ®Google Scholar
• Yun NE, Peng BH, Bertke AS, Borisevich V, Smith JK, Smith JN, Poussard AL, Salazar M, Judy BM, Zacks MA, et al. CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus. Vaccine 2009; 27:4064-73; PMID:19446933; https://doi.org/10.1016/j.vaccine.2009.04.015
   PubMed Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109:5034-9; PMID:22411795; https://doi.org/10.1073/pnas.1200409109
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4:138ra81; PMID:22700957; https://doi.org/10.1126/scitranslmed.3003876
   PubMed Web of Science ®Google Scholar
• Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005; 175:1184-91; https://doi.org/10.4049/jimmunol.175.2.1184
   PubMed Web of Science ®Google Scholar
• Warfield KL, Olinger GG. Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol 2011; 2011:984241; https://doi.org/10.1155/2011/984241
   PubMedGoogle Scholar
• Chapman TJ, Topham DJ. Identification of a unique population of tissue-memory CD4+ T cells in the airways after influenza infection that is dependent on the integrin VLA-1. J Immunol 2010; 184:3841-9; https://doi.org/10.4049/jimmunol.0902281
   PubMed Web of Science ®Google Scholar
• Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol 2012; 12:136-48; PMID:22266691
   PubMed Web of Science ®Google Scholar
• Strutt TM, McKinstry KK, Kuang Y, Bradley LM, Swain SL. Memory CD4+ T-cell-mediated protection depends on secondary effectors that are distinct from and superior to primary effectors. Proc Natl Acad Sci U S A 2012; 109:E2551-60; PMID:22927425; https://doi.org/10.1073/pnas.1205894109
   PubMed Web of Science ®Google Scholar
• McKinstry KK, Strutt TM, Bautista B, Zhang W, Kuang Y, Cooper AM, Swain SL. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2. Nat Commun 2014; 5:5377; PMID:25369785; https://doi.org/10.1038/ncomms6377
   PubMed Web of Science ®Google Scholar
• De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, Martin W. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005; 23:2136-48; PMID:15755584; https://doi.org/10.1016/j.vaccine.2005.01.097
   PubMed Web of Science ®Google Scholar
• De Groot AS, McMurry J, Marcon L, Franco J, Rivera D, Kutzler M, Weiner D, Martin B. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005; 23:2121-31; PMID:15755582; https://doi.org/10.1016/j.vaccine.2005.01.059
   PubMed Web of Science ®Google Scholar
• Gregory SH, Mott S, Phung J, Lee J, Moise L, McMurry JA, Martin W, De Groot AS. Epitope-based vaccination against pneumonic tularemia. Vaccine 2009; 27:5299-306; PMID:19616492; https://doi.org/10.1016/j.vaccine.2009.06.101
   PubMed Web of Science ®Google Scholar
• McMurry JA, Kimball S, Lee JH, Rivera D, Martin W, Weiner DB, Kutzler M, Sherman DR, Kornfeld H, De Groot AS. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med 2007; 7:351-68; PMID:17584075; https://doi.org/10.2174/156652407780831584
   PubMed Web of Science ®Google Scholar
• Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, Martin W, De Groot AS. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011; 29:501-11; PMID:21055490; https://doi.org/10.1016/j.vaccine.2010.10.064
   PubMed Web of Science ®Google Scholar
• Moise L, Tassone R, Latimer H, Terry F, Levitz L, Haran JP, Ross TM, Boyle CM, Martin WD, De Groot AS. Immunization with cross-conserved H1N1 influenza CD4+ T-cell epitopes lowers viral burden in HLA DR3 transgenic mice. Hum Vaccin Immunother 2013; 9:2060-8; PMID:24045788; https://doi.org/10.4161/hv.26511
   PubMed Web of Science ®Google Scholar
• Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011; 29:2085-91; PMID:21236233; https://doi.org/10.1016/j.vaccine.2010.12.130
   PubMed Web of Science ®Google Scholar
• De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001; 19:4385-95; PMID:11483263; https://doi.org/10.1016/S0264-410X(01)00145-1
   PubMed Web of Science ®Google Scholar
• Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73
   PubMed Web of Science ®Google Scholar
• Moise L, McMurry JA, Buus S, Frey S, Martin WD, De Groot AS. In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 2009; 27:6471-9; PMID:19559119; https://doi.org/10.1016/j.vaccine.2009.06.018
   PubMed Web of Science ®Google Scholar
• Schmaljohn C, Vanderzanden L, Bray M, Custer D, Meyer B, Li D, Rossi C, Fuller D, Fuller J, Haynes J, et al. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J Virol 1997; 71:9563-9; PMID:9371620
   PubMed Web of Science ®Google Scholar
• Kong YC, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G, Hämmerling GJ, David CS. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med 1996; 184:1167-72; PMID:9064334; https://doi.org/10.1084/jem.184.3.1167
   PubMed Web of Science ®Google Scholar
• Amante DH, Smith TR, Kiosses BB, Sardesai NY, Humeau LM, Broderick KE. Direct transfection of dendritic cells in the epidermis after plasmid delivery enhanced by surface electroporation. Hum Gene Therapy Methods 2014; 25:315-6; PMID:25470335; https://doi.org/10.1089/hgtb.2014.061
   PubMed Web of Science ®Google Scholar
• Smith TR, Schultheis K, Kiosses WB, Amante DH, Mendoza JM, Stone JC, McCoy JR, Sardesai NY, Broderick KE. DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Therapy Methods Clin Dev 2014; 1:14054; https://doi.org/10.1038/mtm.2014.54
   PubMed Web of Science ®Google Scholar
• Brave A, Nystrom S, Roos AK, Applequist SE. Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses. Immunol Cell Biol 2011; 89:492-6; PMID:20838412; https://doi.org/10.1038/icb.2010.109
   PubMed Web of Science ®Google Scholar
• Howarth M, Elliott T. The processing of antigens delivered as DNA vaccines. Immunol Rev 2004; 199:27-39; PMID:15233724; https://doi.org/10.1111/j.0105-2896.2004.00141.x
   PubMed Web of Science ®Google Scholar
• Hannaman D, Dupuy LC, Ellefsen B, Schmaljohn CS. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation. Vaccine 2016; 34:3607-12; PMID:27206386; https://doi.org/10.1016/j.vaccine.2016.04.077
   PubMed Web of Science ®Google Scholar
• Schmaljohn C, Custer D, VanderZanden L, Spik K, Rossi C, Bray M. Evaluation of tick-borne encephalitis DNA vaccines in monkeys. Virology 1999; 263:166-74; PMID:10544091; https://doi.org/10.1006/viro.1999.9918
   PubMed Web of Science ®Google Scholar
• Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006; 24:4657-66; PMID:16174542; https://doi.org/10.1016/j.vaccine.2005.08.034
   PubMed Web of Science ®Google Scholar
• Hooper JW, Moon JE, Paolino KM, Newcomer R, McLain DE, Josleyn M, Hannaman D, Schmaljohn C. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect 2014; 20(Suppl 5):110-7; PMID:24447183; https://doi.org/10.1111/1469-0691.12553
   PubMed Web of Science ®Google Scholar
• Boudreau EF, Josleyn M, Ullman D, Fisher D, Dalrymple L, Sellers-Myers K, Loudon P, Rusnak J, Rivard R, Schmaljohn C, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine 2012; 30:1951-8; PMID:22248821; https://doi.org/10.1016/j.vaccine.2012.01.024
   PubMed Web of Science ®Google Scholar
• Steele KE, Twenhafel NA. REVIEW PAPER: pathology of animal models of alphavirus encephalitis. Vet Pathol 2010; 47:790-805; PMID:20551475; https://doi.org/10.1177/0300985810372508
   PubMed Web of Science ®Google Scholar
• Hodgson LA, Ludwig GV, Smith JF. Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 1999; 17:1151-60; PMID:10195627; https://doi.org/10.1016/S0264-410X(98)00335-1
   PubMed Web of Science ®Google Scholar
• Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61; PMID:9728532; https://doi.org/10.1086/515386
   PubMed Web of Science ®Google Scholar
• Pratt WD, Gibbs P, Pitt ML, Schmaljohn AL. Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates. Vaccine 1998; 16:1056-64; PMID:9682359; https://doi.org/10.1016/S0264-410X(97)00192-8
   PubMed Web of Science ®Google Scholar